Pravastatin therapy in primary moderate hypercholesterolaemia: Changes in metabolism of apolipoprotein B-containing lipoproteins

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

This study examined the actions of pravastatin on the metabolism of apolipoprotein B (apo B) in very low-, intermediate-, and low-density lipoproteins (VLDL, IDL, and LDL) in 10 patients with primary moderate hypercholesterolaemia. 131I-VLDL apo B was used as a tracer, and appearance of label was followed into IDL apo B and LDL apo B. Compared to placebo, pravastatin therapy reduced levels of cholesterol in total plasma, LDL, VLDL, and IDL cholesterol by 25%, 29%, 31%, and 47%, respectively. Pravastatin treatment also significantly decreased concentrations of apo B in LDL, IDL, and VLDL. The drug significantly reduced the mean production rate for VLDL apo B by 40%, and decreased production rates for LDL apo B in eight of 10 patients. In contrast, fractional catabolic rates (FCRs) were not altered significantly in any of the three lipoprotein fractions on pravastatin therapy. Further, pravastatin produced no consistent changes in LDL particle size, composition, or LDL subclass pattern. Thus pravastatin seemingly reduced input rates for all apo B-containing lipoproteins. Consistent with previous studies, this response was most likely the result of enhanced removal of nascent lipoproteins by increased activity of LDL receptors, although decreased synthesis of apo B in the liver is a possible second action.

Original languageEnglish (US)
Pages (from-to)81-94
Number of pages14
JournalJournal of Internal Medicine
Volume227
Issue number2
StatePublished - 1990

Fingerprint

Pravastatin
Apolipoproteins B
Hypercholesterolemia
Lipoproteins
Therapeutics
IDL Lipoproteins
VLDL Cholesterol
LDL Receptors
LDL Lipoproteins
Particle Size
LDL Cholesterol
Cholesterol
Placebos

Keywords

  • HMG CoA reductase inhibitors
  • hypercholesterolaemia
  • kinetics
  • lovastatin
  • pravastatin

ASJC Scopus subject areas

  • Internal Medicine

Cite this

@article{e47faa4d58a64735b7ead3fbaf4a4d0d,
title = "Pravastatin therapy in primary moderate hypercholesterolaemia: Changes in metabolism of apolipoprotein B-containing lipoproteins",
abstract = "This study examined the actions of pravastatin on the metabolism of apolipoprotein B (apo B) in very low-, intermediate-, and low-density lipoproteins (VLDL, IDL, and LDL) in 10 patients with primary moderate hypercholesterolaemia. 131I-VLDL apo B was used as a tracer, and appearance of label was followed into IDL apo B and LDL apo B. Compared to placebo, pravastatin therapy reduced levels of cholesterol in total plasma, LDL, VLDL, and IDL cholesterol by 25{\%}, 29{\%}, 31{\%}, and 47{\%}, respectively. Pravastatin treatment also significantly decreased concentrations of apo B in LDL, IDL, and VLDL. The drug significantly reduced the mean production rate for VLDL apo B by 40{\%}, and decreased production rates for LDL apo B in eight of 10 patients. In contrast, fractional catabolic rates (FCRs) were not altered significantly in any of the three lipoprotein fractions on pravastatin therapy. Further, pravastatin produced no consistent changes in LDL particle size, composition, or LDL subclass pattern. Thus pravastatin seemingly reduced input rates for all apo B-containing lipoproteins. Consistent with previous studies, this response was most likely the result of enhanced removal of nascent lipoproteins by increased activity of LDL receptors, although decreased synthesis of apo B in the liver is a possible second action.",
keywords = "HMG CoA reductase inhibitors, hypercholesterolaemia, kinetics, lovastatin, pravastatin",
author = "Vega, {Gloria L} and Krauss, {R. M.} and Grundy, {Scott M}",
year = "1990",
language = "English (US)",
volume = "227",
pages = "81--94",
journal = "Journal of Internal Medicine",
issn = "0954-6820",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Pravastatin therapy in primary moderate hypercholesterolaemia

T2 - Changes in metabolism of apolipoprotein B-containing lipoproteins

AU - Vega, Gloria L

AU - Krauss, R. M.

AU - Grundy, Scott M

PY - 1990

Y1 - 1990

N2 - This study examined the actions of pravastatin on the metabolism of apolipoprotein B (apo B) in very low-, intermediate-, and low-density lipoproteins (VLDL, IDL, and LDL) in 10 patients with primary moderate hypercholesterolaemia. 131I-VLDL apo B was used as a tracer, and appearance of label was followed into IDL apo B and LDL apo B. Compared to placebo, pravastatin therapy reduced levels of cholesterol in total plasma, LDL, VLDL, and IDL cholesterol by 25%, 29%, 31%, and 47%, respectively. Pravastatin treatment also significantly decreased concentrations of apo B in LDL, IDL, and VLDL. The drug significantly reduced the mean production rate for VLDL apo B by 40%, and decreased production rates for LDL apo B in eight of 10 patients. In contrast, fractional catabolic rates (FCRs) were not altered significantly in any of the three lipoprotein fractions on pravastatin therapy. Further, pravastatin produced no consistent changes in LDL particle size, composition, or LDL subclass pattern. Thus pravastatin seemingly reduced input rates for all apo B-containing lipoproteins. Consistent with previous studies, this response was most likely the result of enhanced removal of nascent lipoproteins by increased activity of LDL receptors, although decreased synthesis of apo B in the liver is a possible second action.

AB - This study examined the actions of pravastatin on the metabolism of apolipoprotein B (apo B) in very low-, intermediate-, and low-density lipoproteins (VLDL, IDL, and LDL) in 10 patients with primary moderate hypercholesterolaemia. 131I-VLDL apo B was used as a tracer, and appearance of label was followed into IDL apo B and LDL apo B. Compared to placebo, pravastatin therapy reduced levels of cholesterol in total plasma, LDL, VLDL, and IDL cholesterol by 25%, 29%, 31%, and 47%, respectively. Pravastatin treatment also significantly decreased concentrations of apo B in LDL, IDL, and VLDL. The drug significantly reduced the mean production rate for VLDL apo B by 40%, and decreased production rates for LDL apo B in eight of 10 patients. In contrast, fractional catabolic rates (FCRs) were not altered significantly in any of the three lipoprotein fractions on pravastatin therapy. Further, pravastatin produced no consistent changes in LDL particle size, composition, or LDL subclass pattern. Thus pravastatin seemingly reduced input rates for all apo B-containing lipoproteins. Consistent with previous studies, this response was most likely the result of enhanced removal of nascent lipoproteins by increased activity of LDL receptors, although decreased synthesis of apo B in the liver is a possible second action.

KW - HMG CoA reductase inhibitors

KW - hypercholesterolaemia

KW - kinetics

KW - lovastatin

KW - pravastatin

UR - http://www.scopus.com/inward/record.url?scp=0025022375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025022375&partnerID=8YFLogxK

M3 - Article

C2 - 2105373

AN - SCOPUS:0025022375

VL - 227

SP - 81

EP - 94

JO - Journal of Internal Medicine

JF - Journal of Internal Medicine

SN - 0954-6820

IS - 2

ER -